Haisco Pharmaceutical Group (002653.SZ) has obtained a new indication for the innovative drug HSK39797 tablet in the "Drug Clinical Trial Approval Notice".

Haisco Pharmaceutical Group (002653.SZ) announced that the company has recently received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration. After review, the clinical trial application for HSK39297 tablets, which was accepted in August 2025, meets the relevant requirements for drug registration, and permission has been granted to conduct the clinical trial. HSK39297 tablet is a new drug independently developed by the company with proprietary intellectual property rights for the treatment of age-related macular degeneration. Preclinical studies have shown that the drug has clear targets, precise efficacy, and good safety. It is a highly promising small molecule drug with a high benefit/risk ratio for clinical application and broad prospects for clinical use. It is expected to become an effective treatment for AMD, addressing the current lack of effective treatments in clinical practice.